Expected Clinical Course After Autologous Bone Marrow Transplant
Autologous stem cell transplantation (ASCT) in multiple myeloma is not curative but improves median overall survival by approximately 12 months, with treatment-related mortality of only 1-2% and the ability to perform the procedure on an outpatient basis in ~50% of patients 1.
Immediate Post-Transplant Period
The conditioning regimen uses melphalan 200 mg/m² as the preferred standard 1. Following high-dose therapy:
- G-CSF (filgrastim) should be started 1-5 days after high-dose therapy and continued until absolute neutrophil count reaches 2-3 × 10⁹/L 2, 3
- Treatment-related mortality is 1-2% in the modern era 1
- Recovery occurs over 2-3 weeks with appropriate growth factor support
Response Patterns and Remission Duration
Response deepening occurs after ASCT, with studies showing:
- CR/near-CR rates improve from 19-35% post-induction to 40-55% post-ASCT 4, 5
- In patients receiving VRd induction, improved PFS is seen with early ASCT compared to delayed ASCT, though overall survival remains similar 1
- The first relapse typically occurs after 3-4 years following initial diagnosis in the modern therapy era 1
Long-Term Outcomes
Median overall survival approaches 6-10 years depending on patient age at diagnosis 6. Key prognostic factors include:
- Patients achieving ≥VGPR after ASCT have significantly longer PFS (median 41.1 vs 33.5 months) 7
- Standard-risk patients have better outcomes than high-risk cytogenetics
- Each subsequent remission becomes progressively shorter 1
Post-Transplant Management
Lenalidomide maintenance is recommended for most patients as it improves both PFS and OS following ASCT 1. However:
- There is a 2-3 fold increased risk of second cancers, including therapy-related MDS, which must be discussed with patients 1
- High-risk patients should receive bortezomib-based maintenance instead 1
- Consolidation therapy post-ASCT is not recommended based on BMT-CTN trial results 1
Relapse Patterns
Almost all patients eventually relapse, as MM is characterized by multiple remissions and relapses 1:
- Many patients receive 5 or more lines of therapy sequentially over several years
- Salvage ASCT should be considered if the first remission lasted ≥18-36 months 8
- Patients with remission <18 months after first ASCT have poor outcomes with second ASCT (median OS <6 months) 8
Special Considerations
Tandem (double) ASCT has limited role in the modern era:
- No benefit demonstrated in US trials where multiple salvage options are available 1
- May benefit patients not achieving CR/VGPR after first transplant 4, 5
Even patients with progressive disease after induction can respond to ASCT, with 1-year PFS of 70% in primary progressive disease vs 83% in chemosensitive disease 7, 4.
Critical Pitfall
Allogeneic transplantation remains investigational and should be restricted to clinical trials or young patients (<60 years) with high-risk MM in first relapse, given high treatment-related mortality without definitive proof of benefit 1.